Table 2.
The area under the curve for the active metabolite (M15-2) and inactive metabolites (M15-1, M3, and M9-2) of each treatment group (ng · h/mL).
| Study I | Study II | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 10 | Day 1 | Day 8 | Day 23 | |||||||
| Vicagrel (5 mg) | Vicagrel (10 mg) | Vicagrel (15 mg) | Clopidogrel (75 mg) | Vicagrel (5 mg) | Vicagrel (10 mg) | Vicagrel (15 mg) | Clopidogrel (75 mg) | Vicagrel (30 mg) | Vicagrel (7.5 mg) | Vicagrel (7.5 mg + aspirin at 100 mg) | |
| M15-2 | 6.23 (2.34) | 12.2 (4.35) | 22.5 (10.1) | 9.83 (4.42) | 5.84 (2.00) | 11.1 (4.46) | 16.7 (6.03) | 6.50 (2.98) | 47.9 (17.8) | 10.3 (4.45) | 11.7 (4.77) |
| M15-1 | 9.00 (3.49) | 18.3 (7.07) | 30.2 (4.48) | 9.68 (3.67) | 9.66 (2.57) | 19.4 (7.11) | 28.1 (6.49) | 9.26 (4.36) | 64.0 (17.2) | 16.0 (4.84) | 19.1 (5.78) |
| M3 | 81.5 (16.4) | 216 (107) | 370 (85.4) | 270 (81.4) | 108 (33.7) | 221 (80.2) | 427 (131) | 292 (82.6) | 672 (183) | 151 (29.9) | 152 (28.0) |
| M9-2 | 808 (410) | 1,420 (378) | 2,110 (539) | 795 (279) | 958 (286) | 1,740 (663) | 2,720 (954) | 946 (418) | 3,680 (697) | 1,590 (493) | 1,720 (507) |